Nurix Therapeutics (NRIX) Long-Term Investments (2019 - 2024)

Nurix Therapeutics (NRIX) has reported Long-Term Investments for 6 consecutive years, with $9.5 million the latest figure, recorded in Q3 2024.

• In Q3 2024, Long-Term Investments fell 4.15% year-over-year to $9.5 million; the TTM figure through Aug 2024 stood at $9.5 million (down 4.15% YoY), while the FY2023 annual figure was $7.4 million, down 88.38% from the prior year.
• Long-Term Investments rose to $9.5 million in Q3 2024 per NRIX's latest filing, from $9.4 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $137.2 million in Q4 2021 and bottomed at $7.4 million in Q4 2023.
• Historically, Long-Term Investments has averaged $59.3 million across 5 years, with a median of $51.5 million in 2022.
• Annual changes were most pronounced in 2020 — Long-Term Investments jumped 17862.45% — and 2023, when it slumped 88.38%.
• Nurix Therapeutics' Long-Term Investments stood at $90.9 million in 2020, then soared by 50.94% to $137.2 million in 2021, then sank by 53.44% to $63.9 million in 2022, then plunged by 88.38% to $7.4 million in 2023, then increased by 27.64% to $9.5 million in 2024.
• Business Quant data shows NRIX's Long-Term Investments at $9.5 million in Q3 2024, $9.4 million in Q2 2024, and $10.3 million in Q1 2024.